RecruitingNCT07345494
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
Sponsor
Ascendis Pharma A/S
Enrollment
50 participants
Start Date
Feb 18, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.
Eligibility
Sex: FEMALEMin Age: 15 YearsMax Age: 50 Years
Inclusion Criteria3
- Participants aged 15 to 50 years
- Participants with exposure to at least one dose of YORVIPATH at any time within 15 days prior to conception and/or during pregnancy. The timeframe of 15 days prior to conception is calculated based on 5 times the YORVIPATH half life of ~ 60 hours
- Participants providing written informed consent, verbal consent, or eConsent (depending on country regulations) and a Medical Release of Information. For adolescents under the age of majority, verbal or written informed assent by the pregnant minor (where applicable) and verbal or written informed consent by the parent/legal guardian will be obtained.
Exclusion Criteria1
- Pregnancies in which only the male partner is exposed to at least one dose of YORVIPATH.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPalopegteriparatide
Palopegteriparatide prescribed as per normal clinical practice
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07345494
Related Trials
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
NCT070835571 location
A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
NCT070819973 locations
A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
NCT072646341 location
An Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism
NCT075402861 location
Efficacy and Safety of Subcutaneous Injection of XH-02 in the Treatment of Adult Hypoparathyroidism
NCT075307051 location